Can High Uric Acid Cause Fatty Liver?

High uric acid and fatty liver disease are two increasingly common metabolic conditions that frequently occur together, raising the question of whether one can cause the other. Research shows a consistent association between elevated serum uric acid (hyperuricaemia) and non-alcoholic fatty liver disease (NAFLD), with shared drivers including insulin resistance, poor diet and obesity. Understanding this link can help people take earlier action to protect their metabolic health. This article explores the evidence, explains who is most at risk, and outlines what NHS and NICE guidance recommends for managing both conditions.

Is there a link between high uric acid and fatty liver disease?

Research consistently shows an association between hyperuricaemia and NAFLD, with people with high uric acid significantly more likely to have fatty liver, though causation has not been established in UK clinical guidelines.

Research consistently shows an association between elevated serum uric acid levels and non-alcoholic fatty liver disease (NAFLD), though the relationship is not yet classified as a direct cause-and-effect in UK clinical guidelines. Uric acid is a natural waste product formed when the body breaks down purines, compounds found in certain foods and produced during normal cell turnover. When uric acid accumulates in the blood, a condition known as hyperuricaemia, it appears to coincide with metabolic disturbances that also promote fat accumulation in the liver.

Several large observational studies and meta-analyses have found that people with hyperuricaemia are significantly more likely to have NAFLD than those with normal uric acid levels, even after adjusting for other metabolic risk factors such as obesity and type 2 diabetes.^[1][2] However, association does not confirm causation, and both conditions frequently share the same underlying drivers, including insulin resistance, poor diet and a sedentary lifestyle.

It is worth noting that many hepatology bodies now use the terms metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in place of NAFLD and NASH. NICE guidance currently retains the NAFLD and NASH terminology, and this article follows that convention while acknowledging the evolving nomenclature.

NICE guidance on NAFLD (NG49) does not currently list high uric acid as a standalone risk factor, but clinicians are increasingly aware of the metabolic overlap.^[5] If you have been told you have either condition, it is worth discussing both with your GP, as managing one may have a positive effect on the other. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, which may be relevant for those whose metabolic health is a concern.

How does uric acid affect the liver?

Elevated uric acid promotes oxidative stress, inhibits fat metabolism via AMPK suppression and stimulates hepatic fructose production, all of which encourage liver fat accumulation, though most mechanistic evidence comes from animal and laboratory studies.

Elevated uric acid appears to affect the liver through several biological mechanisms, most notably by promoting oxidative stress and inflammation within liver cells. When uric acid levels rise, the enzyme xanthine oxidase, which produces uric acid as a by-product, also generates reactive oxygen species. These molecules can damage hepatocytes (liver cells), impair mitochondrial function and trigger inflammatory pathways that encourage fat deposition.

Uric acid has also been shown in laboratory and animal studies to inhibit a key enzyme called AMP-activated protein kinase (AMPK), which plays a central role in regulating fat metabolism in the liver.^[8] When AMPK activity is reduced, the liver is less efficient at breaking down fatty acids, and triglycerides begin to accumulate, a hallmark of NAFLD. Additionally, uric acid may stimulate the production of fructose within liver cells through a process called the polyol pathway, and fructose itself is a well-recognised driver of hepatic fat accumulation.^[7]

Furthermore, hyperuricaemia is closely linked to insulin resistance, a condition in which cells respond poorly to insulin. The liver responds to insulin resistance by increasing fat synthesis and reducing fat export, compounding the risk of steatosis (fatty change).

It is important to emphasise that much of the mechanistic evidence comes from animal and in vitro studies. The precise contribution of uric acid to liver disease in humans, independent of other metabolic factors, remains an active area of research and causality has not been established. Patients should not interpret these findings as a reason to self-treat, but rather as motivation to seek a comprehensive metabolic assessment from their GP.

What are the symptoms of high uric acid and fatty liver together?

Both conditions are frequently asymptomatic; high uric acid may cause gout attacks, while NAFLD is often found incidentally, though both can occur alongside metabolic syndrome features such as raised blood pressure and abnormal cholesterol.

Both high uric acid and fatty liver disease are frequently silent conditions, meaning many people experience no noticeable symptoms until the conditions have progressed. High uric acid may cause no symptoms at all until it crystallises in joints, leading to gout, which presents as sudden, severe joint pain, swelling, redness and warmth, most commonly in the big toe, ankle or knee. Recurrent gout attacks, or the development of tophi (uric acid crystal deposits under the skin), are signs that uric acid levels have been elevated for some time.

NAFLD in its early stages (simple steatosis) is similarly asymptomatic and is often discovered incidentally during an ultrasound or blood test performed for another reason. It is also important to note that liver enzyme tests (ALT or AST) can be normal in NAFLD, and ultrasound has limited sensitivity for detecting early or mild disease, so a normal result does not rule out the condition.^[9][10] As the condition progresses to non-alcoholic steatohepatitis (NASH), some people report:

• Fatigue and a general sense of feeling unwell

• Mild discomfort or a dull ache in the upper right abdomen

When both conditions are present together, they often occur within a broader cluster of metabolic abnormalities, including raised blood pressure, elevated blood glucose and abnormal cholesterol levels, collectively known as metabolic syndrome.

Seek urgent medical attention if you develop any of the following, as these may indicate serious liver disease: yellowing of the skin or whites of the eyes (jaundice), dark urine or pale stools, vomiting blood or passing black tarry stools, confusion or unusual drowsiness, rapidly increasing abdominal swelling, or severe pain in the upper right abdomen with fever. These symptoms require same-day assessment.

If you experience recurrent gout alongside fatigue or upper abdominal discomfort, or if routine blood tests reveal elevated liver enzymes alongside high uric acid, contact your GP for further assessment. Per NICE NG49, your GP may calculate a FIB-4 or NAFLD fibrosis score to assess the risk of significant liver fibrosis, and may refer you for an enhanced liver fibrosis (ELF) test or to a hepatologist if the score indicates higher risk. Early assessment offers the best outcomes for both conditions.

Who is most at risk of developing both conditions?

People with metabolic syndrome, type 2 diabetes, obesity, chronic kidney disease or high fructose and alcohol intake are at greatest risk, as are men over 40, postmenopausal women and those from South Asian, Chinese or African-Caribbean backgrounds.

People with metabolic syndrome are at the highest risk of developing both hyperuricaemia and NAFLD simultaneously, as the two conditions share a common metabolic foundation. Metabolic syndrome is defined by a cluster of features including central obesity, raised blood pressure, elevated fasting blood glucose, high triglycerides and low HDL cholesterol. Each of these features independently raises the risk of both elevated uric acid and liver fat accumulation.

Specific groups at elevated risk include:

• People with type 2 diabetes or insulin resistance, as impaired insulin signalling promotes both uric acid retention by the kidneys and hepatic fat synthesis

• Those with obesity, particularly abdominal obesity, where visceral fat drives systemic inflammation and metabolic dysregulation

• Men over 40 and postmenopausal women, as oestrogen has a uricosuric effect (it helps the kidneys excrete uric acid), so women's risk rises after the menopause

• People with a high intake of fructose, alcohol or purine-rich foods, such as red meat, organ meats and shellfish

• Those with chronic kidney disease, as reduced kidney function impairs uric acid excretion

• People from South Asian, Chinese, Black African and African-Caribbean backgrounds, who have higher rates of metabolic syndrome and NAFLD, and in whom NICE guidance (including NICE PH46) recognises that metabolic risk may occur at lower BMI thresholds than in the general population

Genetic factors also play a role, with variants in genes regulating uric acid transport and lipid metabolism increasing susceptibility. If you fall into one or more of these categories, case-finding through your GP, including liver function tests, fasting lipids, blood glucose, serum uric acid and calculation of a FIB-4 or NAFLD fibrosis score, is advisable. NICE does not recommend population-wide screening for NAFLD, but assessment in at-risk groups is supported by NG49.^[5]

Can lowering your uric acid levels help protect your liver?

Some studies suggest urate-lowering therapy may improve liver markers, but it is not currently recommended for NAFLD; lifestyle changes that reduce uric acid also independently reduce liver fat, making a holistic metabolic approach most beneficial.

Emerging evidence suggests that reducing elevated uric acid levels may have a beneficial effect on liver health, though this is not yet a formally established treatment strategy in UK clinical guidelines for NAFLD. Several clinical studies have investigated whether urate-lowering therapies, such as allopurinol (which reduces uric acid production by inhibiting xanthine oxidase), are associated with improvements in liver fat content or liver enzyme levels. Some findings are encouraging, but the evidence base is not yet sufficient to recommend urate-lowering therapy specifically for liver protection outside of its licensed indications, and results should be interpreted cautiously given the observational nature of much of this research.

Allopurinol is MHRA-authorised and recognised in NICE Clinical Knowledge Summary (CKS) guidance on gout for the prevention of gout and management of hyperuricaemia in specific clinical contexts, including recurrent gout attacks, tophi and uric acid kidney stones.^[13] It is not currently licensed or recommended as a treatment for NAFLD. If you are already taking allopurinol for gout, it is reasonable to discuss with your GP whether your liver health is being monitored, particularly if you have other metabolic risk factors.

What is clear is that the lifestyle and dietary changes that lower uric acid, such as reducing fructose and alcohol intake, losing weight and increasing physical activity, also independently reduce liver fat. This overlap means that a holistic approach to metabolic health is likely to benefit both conditions simultaneously. Patients should not self-prescribe or adjust prescribed medications without medical supervision. If you are concerned about both your uric acid and liver health, a GP review is the appropriate first step, and referral to a hepatologist or rheumatologist may follow depending on the clinical picture.

Diet and lifestyle changes recommended by NHS guidelines

NICE NG49 and NHS guidance recommend weight loss, reduced fructose and alcohol intake, limiting purine-rich foods and at least 150 minutes of moderate aerobic activity per week as the primary interventions for both hyperuricaemia and NAFLD.

NHS and NICE guidance consistently identifies diet and lifestyle modification as the cornerstone of managing both hyperuricaemia and NAFLD, and the recommended approaches overlap considerably. For NAFLD, clinical guidance supports a sustained reduction in body weight as the most effective intervention for reducing liver fat and inflammation. Evidence cited in guidelines such as those from the British Society of Gastroenterology (BSG) suggests that weight loss in the region of 7 to 10 per cent is associated with meaningful reductions in liver inflammation and fibrosis, while even modest weight loss of 3 to 5 per cent can reduce hepatic steatosis.^[5][14] NICE NG49 recommends weight loss as a central intervention but advises discussing realistic, individualised targets with a healthcare professional rather than applying a single figure to all patients.

Key dietary recommendations include:

• Reducing free sugars and fructose, found in sugary drinks, fruit juices, sweets and ultra-processed foods, as fructose drives both uric acid production and hepatic fat synthesis

• Limiting alcohol, which raises uric acid levels and contributes directly to liver fat accumulation; UK Chief Medical Officers' low-risk drinking guidelines advise no more than 14 units per week, spread across at least three days, with several drink-free days each week^[15]

• Reducing purine-rich foods such as red meat, organ meats, game and shellfish, which increase uric acid production, as recommended in NICE CKS guidance on gout

• Increasing dietary fibre through vegetables, wholegrains and legumes, which supports a healthy gut microbiome and reduces systemic inflammation

• Staying well hydrated, as adequate fluid intake supports renal uric acid excretion

Physical activity is equally important. UK Chief Medical Officers' physical activity guidelines, reflected in NHS Live Well advice, recommend at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking or cycling, alongside muscle-strengthening activities on two or more days.^[16][17] Regular exercise improves insulin sensitivity and reduces liver fat, and there is evidence that it can lower serum uric acid levels as part of an overall improvement in metabolic health.

If lifestyle changes alone are insufficient, your GP can assess whether pharmacological support is appropriate. Referral to a dietitian may also be offered through your local Integrated Care Board (ICB) commissioned services.

Scientific References

1. Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: meta-analysis (PMID 37305378).
2. The Correlation Between Serum Uric Acid and Metabolic Dysfunction-Associated Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis (PMID 41039166).
3. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score: a systematic review and meta-analysis (PMID 28639970).
4. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis (PMID 26738417).
5. Metabolic dysfunction-associated steatotic liver disease (NAFLD): diagnosis and management (NG49).
6. Hepatic Accumulation of Hypoxanthine: A Link Between Hyperuricemia and Nonalcoholic Fatty Liver Disease (PMID 33966916).
7. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats (PMID 30651350).
8. Fructose surges damage hepatic adenosyl-monophosphate-dependent kinase and lead to increased lipogenesis and hepatic insulin resistance (PMID 27372863).
9. Metabolic-dysfunction associated steatotic liver disease: clinical features and noninvasive methods of detection in young adults with obesity (PMID 42467953).
10. The use of simple tests to predict biopsy-proven steatohepatitis in people with type 2 diabetes (PMID 39919007).
11. Using the ELF test, FIB-4 and NAFLD fibrosis score to assess liver fibrosis (PMID 37088311).
12. Appendix A1: Summary of evidence from surveillance (PH46) — BMI thresholds for ethnic minority groups.
13. Gout — NICE Clinical Knowledge Summary.
14. Non-alcoholic fatty liver disease (NAFLD) — NHS.
15. Alcohol consumption: advice on low risk drinking — UK Chief Medical Officers' guidelines.
16. Physical activity guidelines: UK Chief Medical Officers' report.
17. Physical activity guidelines for adults aged 19 to 64 — NHS Live Well.

Frequently Asked Questions